Institute of Pharmaceutics, College of Pharmaceutics Sciences, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Department of Radiology, Lishui Hospital of Zhejiang University, Lishui, 323000, People's Republic of China.
Int J Nanomedicine. 2021 Jul 8;16:4693-4712. doi: 10.2147/IJN.S314506. eCollection 2021.
Benefiting from the rapid development of nanotechnology, photodynamic therapy (PDT) is arising as a novel non-invasive clinical treatment for specific cancers, which exerts direct efficacy in destroying primary tumors by generating excessive cytotoxic reactive oxygen species (ROS). Notably, PDT-induced cell death is related to T cell-mediated antitumor immune responses through induction of immunogenic cell death (ICD). However, ICD elicited via PDT is not strong enough and is limited by immunosuppressive tumor microenvironment (ITM). Therefore, it is necessary to improve PDT efficacy through enhancing ICD with the combination of synergistic tumor therapies. Herein, the recent progress of nanomaterials-based PDT combined with chemotherapy, photothermal therapy, radiotherapy, and immunotherapy, employing ICD-boosted treatments is reviewed. An outlook about the future application in clinics of nanomaterials-based PDT strategies is also mentioned.
得益于纳米技术的快速发展,光动力疗法(PDT)作为一种治疗特定癌症的新型非侵入性临床治疗方法正在兴起,它通过产生过多的细胞毒性活性氧(ROS)直接发挥破坏原发性肿瘤的作用。值得注意的是,PDT 诱导的细胞死亡通过诱导免疫原性细胞死亡(ICD)与 T 细胞介导的抗肿瘤免疫反应有关。然而,PDT 引发的 ICD 还不够强,并且受到免疫抑制性肿瘤微环境(ITM)的限制。因此,有必要通过结合协同肿瘤治疗来增强 ICD,从而提高 PDT 的疗效。本文综述了基于纳米材料的 PDT 与化疗、光热疗法、放射疗法和免疫疗法相结合,利用 ICD 增强治疗的最新进展。还提到了基于纳米材料的 PDT 策略在临床中的未来应用前景。